Clinical trial
Docetaxel in Combination With Iressa in Previously Treated Patients With…
NCT00137761 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00137761 |
|---|---|
| Title | Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer |
| Official title | A Phase II Study of Docetaxel in Combination With ZD 1839 (IRESSA) in Previously Treated Patients With Metastatic Pancreatic Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Beth Israel Deaconess Medical Center Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Pancreatic Carcinoma |
| Intervention type | Drug |
| Interventions | ZD 1839, Docetaxel |
| Enrollment | 32 |
| Start date | Oct 1, 2004 |
| Primary completion | Jun 1, 2007 |
| Completion | Mar 1, 2009 |
| First posted | Aug 30, 2005 |
| Last update posted | Nov 2, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: